IPP Bureau
USFDA concludes inspection of NATCO’s Pharma Division, Kothur
By IPP Bureau - June 20, 2025
The company received seven observations in the Form-483
Sanner commences manufacturing critical injection-molded components in USA
By IPP Bureau - June 20, 2025
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
UFlex introduces FSSAI compliant single-pellet solution for food packaging
By IPP Bureau - June 20, 2025
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Briefs: Hikal and Sun Pharma
By IPP Bureau - June 17, 2025
Sun Pharma gets 8 observations from USFDA for Halol facility
Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
By IPP Bureau - June 17, 2025
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
By IPP Bureau - June 17, 2025
The company received one observation in the Form-483
USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
By IPP Bureau - June 17, 2025
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
By IPP Bureau - June 16, 2025
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
By IPP Bureau - June 16, 2025
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
By IPP Bureau - June 16, 2025
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
By IPP Bureau - June 16, 2025
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery
By IPP Bureau - June 13, 2025
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
By IPP Bureau - June 13, 2025
Now approved for both acute and chronic HCV in adults and children aged 3 and above
